News Agency
Men's Weekly

Akeso Announced The Lancet Oncology Publishes Promising Clinical Results from Cadonilimab in Patients with Advanced Solid Tumours (COMPASSION-03/AK104-201)

  • Written by PR Newswire

HONG KONG, Oct. 12, 2023 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso") announced that the results of the multicenter, open-label Phase Ib/II clinical trial (COMPASSION-03/AK104-201) for cadonilimab (PD-1/CTLA-4 bispecific antibody), the globally first bispecific IO drug used to treat advanced solid tumors, have been published in the October 2 iss...

Read more: Akeso Announced The Lancet Oncology Publishes Promising Clinical Results from Cadonilimab in...

Defence Recruitment: Building Australia’s Future Security Workforce

Australia’s defence sector is one of the nation’s most vital and rapidly evolving industries, offering stable and rewarding careers for individuals committed to protecting national interests. With the growing need for advanced technologies, cybersecurity, and global defence partnerships, opportunities in defence... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion